World alliance against antibiotic resistance: The WAAAR declaration against antibiotic resistance

Jean Carlet, on behalf of the members of the WAAAR

Received 26 September 2014; accepted 3 October 2014
Available online 17 December 2014

Abstract We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservation of the efficacy of antibiotics and to stabilization of antibiotic-susceptible bacterial ecosystems should be global goals.

© 2014 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.

Keywords
Antibiotic resistance; WAAAR

Alianza Mundial contra la resistencia antibiótica. Declaración contra la resistencia antibiótica

Resumen Debemos cambiar la forma como se utilizan los antibióticos, adoptando estrategias proactivas, de igual manera que se protegen las especies en peligro de extinción. Preservar la eficacia de los antibióticos y mantener la susceptibilidad de los ecosistemas bacterianos deben ser objetivos globales.

© 2014 Elsevier España, S.L.U. y SEMICYUC. Todos los derechos reservados.

We must change how antibiotics are used and adopt proactive strategies, similar to those used to save endangered species. Preservation of the efficacy of antibiotics and to stabilization of antibiotic-susceptible bacterial ecosystems should be global goals.

We urge all of you to participate in this crusade, in your own field of interest. The medical miracle of antibiotic therapy must be protected – this is a global priority and our duty. Please, help us to act NOW, by supporting this declaration, to promote wiser use of antibiotics in animal and human health, and the necessary accompanying political actions to support better education, integrated surveillance for public health action, and research.

The increase in antibiotic resistant bacteria poses a major healthcare threat. In the face of an almost complete absence of new antimicrobial drugs in development, antibiotic resistance (ABR) has become one of the main public health problems of our time. Antibiotics are a unique class of medications because of their potential societal impact; use of an antibiotic in a single patient can select for ABR that can spread to other people, animals, and the environment, making an antibacterial used in one patient ineffective for many others. Bacterial resistance can evolve rapidly. As bacteria acquire resistance mechanisms, the altered bacterial

E-mail address: jeancarlet@gmail.com

1 See Appendix.

http://dx.doi.org/10.1016/j.medin.2014.10.004
0210-5691/© 2014 Elsevier España, S.L.U. and SEMICYUC. All rights reserved.
genetic material coding for resistance mechanisms can be transmitted at times readily between bacteria, broadening the reach and extent of resistance. Treatment failures because of multidrug resistant (MDR) bacteria, once rare, notable, and limited to hospitals, now occur very commonly in hospitals and increasingly in the community as well. It is estimated that a minimum of 25,000 patients in Europe and 23,000 in the USA die each year from infections caused by resistant bacteria. The cost of antibiotic resistance is tremendous, whether measured as the personal and societal burden of illness, death rates, or healthcare costs.

Although it is a never-ending phenomenon, antibiotic resistance is directly related to the volume of antibiotics used. We are using increasing amounts of antibiotics in health care and agriculture, and discharging these active drugs into the environment. The impact of widespread antibiotic use is enormous, promoting the development and dissemination of antimicrobial resistance.

Safeguarding antibiotics will require a concerted effort by citizens, patients and prescribers. The primary goal of WAAAR is to raise awareness about the urgency and magnitude of the threat and to promote an international dialogue to assist in effective responses. The Alliance, in particular through this declaration, is dedicated to actively promoting antibiotic preservation and to raising awareness among antibiotic prescribers, politicians and policy-makers, patient safety and advocacy groups, the pharmaceutical industry, international health organizations, and the general population. Individual actions, no matter how well intended, are doomed to failure unless there is an international dialogue, a common sense of purpose, and broad consensus on how best to proceed.

**WAAAR advocates for the following 10 actions**

1. **Promotion of awareness of all the stakeholders – including the general public – of the threat represented by antibiotic resistance**
   - Strong cooperation among international political, economic and public health organizations, which, all together, must take the lead of this action against antibiotic resistance.

2. **Organization, in each country, ideally by Ministries of Health or regulatory bodies, of a financed national plan for the containment of antibiotic resistance, with the participation of all stakeholders, including patient advocacy groups**

3. **Continuous access to antibiotics of assured quality, especially in middle and low income countries**

4. **WAAAR advocates for the following 10 actions Integrated Surveillance of antibiotic resistance (ABR) and antibiotic use**
   - Standardized monitoring of antibiotic use and resistance at institution, regional, and country (comprehensive national data instead) level (through a Centres for Diseases Control and Prevention model) to allow comparative statistics (benchmarking), to be updated preferably in real-time and at least every 12 months. This will require adequate laboratory capacity using international standardized methods that may be facilitated by a centralized technologic coordinating infrastructure and information technology

5. **Use of diagnostic tests**
   - Appropriate use of existing diagnostic tests and development and implementation of new rapid, cost-effective and accurate diagnostic tests, adapted to the local context, to aid in distinguishing bacterial and nonbacterial etiologies. Rapid diagnostics may help clinicians avoid unnecessary treatments, rapidly select appropriate targeted therapies and inform the duration of treatment

6. **Antibiotic stewardship (prudent, controlled and monitored approaches to the use of antibiotics)**
   - In humans (hospitals, long term care facilities and primary care).
   - In animals (animal husbandry, agriculture, aquaculture and animal health/veterinary setting), in a “one health” philosophy.
   - Progressive elimination of the “over the counter” (i.e. available without a prescription) access to antibiotics (systemic and topicals) for humans or animals.
   - Ban of the use of antibiotics as growth promotion in food animals, and exceptional use in prophylaxis.
   - Rational use of metaphylaxis (Prophylaxis when some animals in the livestock are sick, or at high risk to be sick), and of animal treatment.
   - Limitation of the use of critically important antibiotics in humans and animals (e.g., carbapenems).

7. **Educational efforts for change**
   - Educational programmes directed at children/teenagers on antibiotics, bacterial resistance, and infection control (e-Bug model).
   - Development of large coordinated, effective information and awareness campaigns directed at the public on expectations about the rational/appropriate use of antibiotics.
   - Continuous education and training programmes in the curriculum for all health care professionals in all settings (veterinarians, medical, dental, nursing, pharmacy and allied health care schools) and continuing professional education programmes, on the rational use of antibiotics, including indications, dosing and duration of therapy. Education of farmers.

8. **Containment of bacterial transmission and prevention of infection**
   - Promotion of universal hand hygiene and all infection control interventions that have been proven to reduce rates of resistance.
   - Relentless efforts to prevent transmission of MDR organisms in healthcare, food production and animal husbandry.
   - Programmes to limit the contamination of drinking water with MDR bacteria, as well as contamination of the environment.
   - Promotion of the use of available vaccines, in humans and animals.

9. **Basic and applied research, and development of new antibiotics**
   - Increased support for basic and applied research aiming at curbing bacterial resistance in human and veterinary medicine.
• Use of the principles of orphan drugs for new antibiotics.
• Incentives to stimulate research of new drugs (antibiotics and novel compounds) and vaccines via regulatory pathways that allow for fast track development.
• New economic business models to support the cost of innovation while safeguarding public health interests.

10. Request for UNESCO to include the "concept of antibiotic" in the list of the intangible cultural heritage.

Funding

No funding.

Conflict of interest

No conflict of interest.

Appendix.

WAAAR is a group of 700 individuals from 55 different countries representing all the key stakeholders (physicians, veterinarians, microbiologists, surgeons, pharmacists, nurses, evolutionary biologists, ecologists, environmentalists, patient advocacy groups). The Alliance receives support from more than 140 learned societies or professional groups throughout the world. WAAAR is a nonprofit organization open to professionals and consumers worldwide. WAAAR receives no funding from the pharmaceutical industry.

Supporting individuals

Laurent Aaron (France), Mohamed Salah Abassi (Tunisia), Lilian Abbo (USA), Oladipo Aboderin (Nigeria), Edward Abraham (USA), Fekri Abroug (Tunisia), Jacques Acar (France), Wafa Achour (Tunisia), Javier Adachi (USA), Seif Al-Abri (Oman), Haifaa Al-Mousa (Kuwait), Antonio Albaya-Moreno (Spain), Corinne Alberti (France), Serge Alfandari (France), Amani Alnim (Saudi Arabia), Celia Alpuche Aranda (Mexico), Francisco Alvarez de Lerma (Spain), Fatma Amer (Egypt), Antoine Andremont (France), François Angoulvant (France), Maryvonne Anguill (France), Massimo Antonelli (Italy), Eleni Antoniadou (Greece), Guillaume Arlet (France), Apostolos Armaganidis (Greece), Anne Arnera (France), Antonio Artigas (Spain), Claude Attali (France), Frédéric Aubier (France), Jean-Pierre Aubert (France), Bernard Augereau (France), Martine Aupée (France), Olfa Bahri (Tunisia), Françoise Ballereau (France), Gérard Bapt (France), Fernando Baquero (Spain), Timothy Barkhan (Singapore), Ouahid Barouti (Morocco), Marie-Anne Barthelemy (France), Greg Barton (UK), Davide Bastoni (Italy), Michel Baussier (France), Luis Bavestrrello (Chile), Birgit Beger (Belgium), Samuel Benenson (Israel), Fethi Bensalem (France), Guillaume Béraud (France), Frédérique Bergeheau (France), Gordon Bernard (USA), Philippe Berthelot (France), Xavier Bertrand (France), Frédérique Beuhrory-Sassus (France), Pascal Beuret (France), John Billington (USA), Jacques Birgé (France), Sandra Biscardi (France), Luis Blanch (Spain), Hervé Blanchard (France), Thomas Bleck (USA), Joseph Blondeau (Canada), François Blot (France), Borgey (France), Alain Bousquet-Méhou (France), Jean Brami (France), Christophe Brard (France), Stéphane Bretegagne (France), Cédric Bretonnière (France), Adrian Brink (South Africa), Sheldon Brown (USA), Catherine Bruant-Rodier (France), Christian Brun-Buisson (France), Fabrice Bruneel (France), Frederico Bruzzi de Carvalho (Brazil), Christophe Buhot (France), Huda Bukharie (Saudi Arabia), André Cabié (France), Thierry Calandra (Switzerland), Isabelle Caniaux (France), Manuela Caniça (Portugal), Rafael Canton (Spain), Philippe Carenc (France), Camille Carlet (France), Claude Carlet (France), Florian Carlet (France), Jean Carlet (France), Romain Carlet (France), Otto Cars (Sweden), Manuel Cassiano-Neves (Portugal), Bernard Castan (France), Vincent Castellan (France), France Cazenave-Roblot (France), Alain-Michel Ceretti (France), Jean-Charles Chakarian (France), Ludwine Chalumeau-Lemoine (France), John Chandy (USA), Bernard Chanfreau (France), Jean Chastre (France), Robert Chauisset (France), Pascal Chavanet (France), William Cheadle (USA), Jean-Daniel Cichic (France), Christian Chidiac (France), Olivier Chosidow (France), Natalia Chueca (Spain), Jon Cohen (UK), Robert Cohen (France), Peter Collignon (Australia), Frédéric Collot (France), Patrick Coloby (France), John Conly (Canada), Cruz Cordero (Brazil), Catherine Cordonnier (France), Alejandra Corso (Argentina), Sara Cosgrove (USA), René Courcol (France), Steve Crane (USA), Donald Craven (USA), Adnina Crespin (France), Marcos Cyrillo (Brazil), Pierre-Eric Danin (France), Jan De Waele (Belgium), Pierre Dellamonica (France), E. Patchen Dellinger (USA), Philip Dellinger (USA), Jean Delmont (France), Eric Denes (France), George Dimopoulos (Greece), Dimitri Drekonja (USA), Anahi Deser Mansilla (Mexico), Pierre-Louis druais (France), Sylvie Dufour-Pieprat (France), Catherine Dumartin (France), Martin Dünser (Austria), Michel Dupont (France), Ricardo Durlach (Argentina), Oliver Dyar (UK), Gabriela Echaniz (Mexico), Paul Edelstein (USA), Philippe Eggimann (Switzerland), Mohamed Elghonemi (Egypt), Naima Elmadghri (Morocco), Rehab Elsaid (Egypt), Rehab Elsokari (Egypt), Dan Engelhard (Israel), Jacques Fabry (France), Christopher Farmer (USA), J. Fernandez (Spain), Simon Finner (Australia), Patricia Finn (USA), Katrin Feldstedt (Israel), Daniel Floret (France), Francesco Flizaro (France), Jacinthe Foegle (France), Xavier Forceville (France), Sandra Fourrier (France), Irène Franchon (France), Alexander Friedric (The Netherlands), Pascal Funuel (France), Didier Gaillard (France), Jacques Gaillat (France), Tatiana Galperine (France), Karine Gambarotto (France), Bernard Garo (France), Maite Garroute-Orgeas (France), Petra Gastmeier (Germany), Jean-Yves Gauchot (France), Remy Gauzit (France), Gaëtan Gavinzi (France), Louise Gazagne (France), Julie Gerberding (USA), Abdul Ghafur (India), Evangelos Giamarellos-Benzouil (Greece), Eleni Giamarelou (Greece), Marine Girard (France), Mark Gilchrist (UK), Jacques Gilquin (France), Fernando Giltsanz (Spain), Marek Gniadkowski (Poland), Charalampos Gogos (Greece), Don Goldman (USA), Florence Gordon (France), Thomas Gottleib (Australia), Ian Gould (UK), Joao Gouveia (Portugal), Jennifer Grant (Canada), Lindsay Grason (Australia), Alix Greder (France), Hajo Grundman (The Netherlands), Eric Guaguere (France), Gwenaëlle Guérout-Locher (France), Benoit Guery (France), Bertrand Guidet (France), Catherine Guignabert (France), Pradip Gupta (India), Sanjay Gupta
World alliance against antibiotic resistance 37

(United Kingdom), Mohan Gurjar (India), Manuel Guzman (Venezuela), Joseph Jajjar (France), Noha Hammad (Egypt), Anette Hammerum (Denmark), Hakan Hanberg (Sweden), Regina Hanke (Germany), Stephan Harbarth (Switzerland), Anita Harel (France), Elisabeth Heibourg (Austria), Isabelle Hermes (France), Jean-Pierre Hermet (France), Bernard Hirschel (Switzerland), Bruno Hoen (France), Aidan Hollis (Canada), Xiao Honghong (China), David Hooper (USA), Juan Pablo Horcajada (Spain), Bruno Housset (France), Waleria Hryniewicz (Poland), Li Yang Hsu (Singapore), Susan Huang (USA), James Hughes (USA), Jean-Louis Hunault (France), Lotte Jakobsen (Denmark), Nordahl Jalil (Malaysia), Hilde Jansens (Belgium), Vincent Jarlier (France), William Jarron (France), Dominique Jean (France), Matjaz Jereb (Slovenia), James Johnson (USA), Marie-Laure Joly-Guillou (France), Olivier Jonquet (France), Guillaume Kac (France), Deogracia Kaddu-Mulindwa (Uganda), Mitsuo Kamata (Japan), Badreddine Khlabi (Tunisia), Eui-Chong Kim (South Korea), Dorothee Kinde Gazard (Benin), Keith Klugman (USA), Stacey Klutts (USA), Jan Klyutmans (The Netherlands), Marin Kollef (USA), Despoina Koulenti (Greece), Michael Kresken (Germany), Francois Lacois (France), Jean-Patrick Lajonchere (France), Nathalie Landgraf (France), Gerard Larrousse (France), Pierre-Francois Laterre (Belgium), Anne-Marie Lavenaire (France), Thierry Lavigne (France), Ramon Laxaminarayan (USA), Thi Anh Thu Le (Vietnam), Françoise Leblanc-Jouffre (France), Nam Yong Lee (South Korea), Olivier Lehiany (France), Herve Lelouet (France), Frederique Lemanach-Kergueris (France), Alain Lepape (France), Joel Leroy (France), Xavier Lescure (France), Mitchell Levy (USA), Gabriel Levy-Hara (Argentina), Ling Moi Lin (Singapore), Jeffrey Lipman (Australia), Joel Livartowski (France), David Looke (Australia), Fernando Luis Lopez Cardozo (Brazil), Francisco Lopez Medrano (Spain), Anne Lottenh (France), Jean Christophe Lucte (France), David Lupande (D.R. Congo), Jean-Yves Madec (France), Jean-Luc Mainardi (France), Sundaresan Maiyilagan (Mauritius), Jordi Mancebo (Spain), Franck Mansour-Adeoti (France), Enrique Maravi (Spain), Bruno Marchou (France), Darcy Marciniuk (Canada), John Marshall (Canada), Claude Martin (France), David Martin (USA), Luis Martinez-Martinez (Spain), Alain Martinot (France), Emilio Maseda (Spain), Dimitrios Matamis (Greece), Sophie Matheron (France), Ricardo Matos (Portugal), Marie Matthews (UK), Thierry May (France), Thierry Mayet (France), John McGowan (USA), Shaheen Mehtar (South Africa), Jose Mario Meira Teles (Brazil), Marc Mendelson (South Africa), Christian Michelot (France), Albert Mifsud (UK), Magolia Mikaszewska-Sokolowicz (Poland), Jessica Minion (Canada), Christelle Miquel (France), Jean-Paul Mira (France), Jose Miro (Spain), Benoit Misset (France), Jean-Jacques Monot (France), Philippe Montravers (France), Joy Mootien (France), Rui Moreno (Portugal), Andrew Morris (USA), Gerard Moulin (France), Cécile Mourlan (France), Gilbert Mouthon (France), Wafaa Mowafy (Egypt), Elke Muhl (Germany), A. Muruganathan (India), Enani Mushida (Saudi Arabia), Babacar N'Doye (Senegal), Aburjania Nana (USA), Michael Niedermaier (USA), Gerard Nitenberg (France), Patrice Nordman (France), Assumphta Novira (Spain), Cyrille Nowak (France), Iruka Okeke (USA), Pedro Maria Olaechea (Spain), Abeer Omar (Kuwait), Steve Opal (USA), Carlos Ortiz Leyba (Spain), Bauke Oudega (The Netherlands), Eric Oziol (France), Bernard Page (France), Jose Arthur Paiva (Portugal), Lucy Palmer (USA), Mercedes Palomar-Martinez (Spain), Pierre Parneix (France), Didier Payen de la Gardenerie (France), Eli Perencevich (USA), Trish Perl (USA), Christian Perronne (France), Georg Peters (Germany), Matthew Peters (Australia), Dominique Peyramond (France), Francois Phillipart (France), Didier Pittet (Switzerland), Jean-Francois Pittet (USA), Patrick Plediat (France), Mathias Pletz (Germany), Marie-Cécile Ploy (France), Florence Pospelis (France), Pascal Pouedras (France), Garyphallia Poulakou (Greece), Anny Pourinho (France), Peter Pronovost (USA), Celine Pulcini (France), Massimo Puoti (Italy), Shanmugam Puvanendiram (Sri Lanka), Michael Quintel (Germany), Christian Rabaud (France), Claude Rambaud (France), Helena Ramos (Portugal), Ossama Rassia (Egypt), Josette Raymond (France), Bernard Regnier (France), Konrad Reinhardt (Germany), Jordi Rello (Condomines (Spain), Jean-Claude Revil (Revel?), (France), Agnes Riché (France), Paul Richman (USA), Rosana Richmann (Brazil), Viviana Rodriguez (Argentina), Jesus Rodriguez-Bano (Spain), Olivier Romain (France), Karine Romand (France), Elisabeth Rossines (France), Monique Rothondeur (France), Jean-Francois Rousselot (France), Ethan Rubinstein (Canada), Vladimir Rudnov (Russia), Narender Saini (India), Dominique Salmon (France), Reinaldo Salomao (Brazil), Miguel Sanchez Garcia (Spain), Antonio Santos-Bouza (Spain), Marie-Caude Saux (France), Anne Savey (France), Lynora Saxon (Canada), Benoit Schlemmer (France), Jean-Luc Schmit (France), Dietmar Schneider (Germany), Janet Schoemaker (USA), Sanjeev Singh (India), Jordi Sole-Violan (Spain), Sara Soto (France), Jean-Paul Stahl (France), Annabelle Stoclin (France), Alexis Tabah (Australia), Jean-Philippe Tabut (France), Paul Anamtharajah Tambyah (Singapore), Fabienne Tamion (France), Phillip Tar (USA), Pierre Tattevin (France), Fred Tenover (USA), Nicolas Terzi (France), Marthe Than Lecompte (Switzerland), Jonathan Theodore (France), Didier Thevenin (France), Philippe Thelenov (France), Laurent Thiriet (France), Carol Thompson (USA), Joseph Thurn (USA), Glenn Tillotson (USA), Hanen Tiouri (Tunisia), Antonio Torres (Spain), Francois Treomolières (France), Michel Troadec (France), Rabiul Umar (Nigeria), Garance Upham (France), Carl Urban (USA), Jan Vaarten (-), Dominique Valla (France), Nathalie Van Der Mee-Marquet (France), Jos Van Der Meer (The Netherlands), Tom Van Der Poll (The Netherlands), Jacques Vancel (France), Philippe Vanhems (France), Remi Varin (France), Emmanuelle Varon (France), David Vaughan (USA), Marc Veilly (France), K. Vijayakumaran (India), Alvaro Villanueva (Columbia), Jean-Louis Vincent (Belgium), Virginie Vitrat (France), Andreas Voss (The Netherlands), Robert Wachter (USA), Tim Walsh (UK), Peter Wark (Australia), Grant Waterer (Australia), Henrik Caspar Wegener (Denmark), Pierre Weinbreck (France), Robert Weinstein (USA), Scott Weissman (USA), Jeanine Wiener-Kronish (USA), Alexander Wilmer (Belgium), Benjamin Wyplosz (France), Ibrahim Yacoub-Agha (France), Melanie Young (USA), Ibrahim Yusuf (Nigeria), Emile Zein (Lebanon), George Zhanel (Canada), Stephen Zinner (USA), Josep Zoungrana (Burkina Faso), Nadezhda Zubareva (Russia).

Supporting national and international agencies
Centres for Disease Control and prevention (CDC).

Supporting medical organizations
American College of Chest Physicians (ACCP) (Darci Marciniuk), American Society of Microbiology (ASM) (Janet Schoemaker), American Thoracic Society (ATS) (Patricia
World alliance against antibiotic resistance

Monique Rothan-Tondeur, Collège des Enseignants de Maladies Infectieuses (CMIT) (Christian Michelet), Collège National de Médecine Générale (CNMG), Collège National des Généralistes Enseignants (CNGE) (Pierre Louis Druais), Comité de Pilotage des Réseaux de Surveillance ATB et BMR Sud Est, Doctors Without Borders/Médecins Sans Frontières (Arlène Chua, Richard Murphy), Egyptian Patient Safety Association (EPSA) (Ossama Rassla), ESGAP working group (ESCMID) (Jordi Rello), Fédération des Spécialités Médicales (FSM), Fédération Française d’Infectiologie (FFI) (Christian Perrone), Fédération Française de Pneumologie (FFP) (Bruno Housset), Groupe de Pathologie Infectieuse en Pédiatrie (GPIP) (Robert Cohen), Grupo de Enfermedades Infectiosas y Sepsis De la Sociedad Española de Medicina Intensiva, Hellenic Sepsis Study Group (Gogos Charalambos, Evangelos Giamarelos-Bourboulis), Infection Control Directorate (Ministry of Health-Kuwait), Infection Prevention and Control African Network (IPCAN) (Shaheen Mehtar), Institut de Recherche en Médecine Générale (IRMG), Institut Maurice Rapin (IMR) (Christian Brun-Buisson), International Forum for Acute Care Trialists (InFACT) (John Marshal), International Sepsis Forum (Tom Van Der Poll), Le Forum des Bio-hygienistes, Ligue Africaine des Associations pour la Sécurité des Patients (LIASEP), Medqual (F. Ballereau), National Committee for the Proper Use of Antibiotics (Ministry of Health-Kuwait), Observatoire du Risque Infectieux en Gériatrie (ORIG) (Monique Rotha-Tondeur), Observatoire National d’Épidémiologie de la Resistance Bactérienne aux antibiotiques (ONERBA) (Marie-Hélène Nicolas-Chanoine), Portuguese Intersectorial Alliance for the Preservation of the Antibiotics (APAPA) (Jose Arthur Paiva), Programme National de Lutte contre l’Infection Nosocomiale (PRONALIN), Sénégal (Babacar N'Doye), Réseau International pour la Planification et l’Amélioration de la Qualité des Soins en Afrique (RIPAQS) (Bernard Chanfreau), Réseau Sud-Est de Surveillance et de Prévention des Bactéries Multirésistantes aux Antibiotiques, South African Antibiotic Stewardship programme (Adrian Brink), Spanish Network for Research in Infectious Diseases (REIPI) (Jesus Rodriguez-Bano), Safe Observer International (SOI) (Garance Upham), The Bekele Afessa Initiative to Improve Sepsis Care in Resource-Limited Areas (Joseph Christopher Farmer), The Canadian Antimicrobial Resistance Alliance (CARA), The Eastern Mediterranean Regional Network for Infection Control (EMRNI) (Ossama Rassla), The Gulf Cooperation council (GCC) (Hanan Balkhy).